A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mesothelioma
- Pancreatic Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Orion Corporation, Orion Pharma
- Last updated on ClinicalTrials.gov
- May 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- NEXT Oncology · Irving, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.